Modality
Radioligand
MOA
DLL3 ADC
Target
FGFR
Pathway
Fibrosis
NASH
Development Pipeline
Preclinical
~Dec 2017
→ ~Mar 2019
Phase 1
Jun 2019
→ Nov 2029
Phase 1Current
NCT04359798
728 pts·NASH
2019-06→2025-12·Completed
NCT03063945
2,732 pts·NASH
2023-07→2029-11·Completed
3,460 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-12-034mo agoInterim· NASH
2029-11-273.7y awayInterim· NASH
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1
Complet…
P1
Complet…
Catalysts
Interim
2025-12-03 · 4mo ago
NASH
Interim
2029-11-27 · 3.7y away
NASH
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04359798 | Phase 1 | NASH | Completed | 728 | NT-proBNP |
| NCT03063945 | Phase 1 | NASH | Completed | 2732 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| Tixatapinarof | Recursion | Approved | FGFR | |
| Tixatapinarof | Arvinas | Phase 1/2 | CDK2 | |
| ABS-5770 | Absci | Preclinical | FGFR |